Effect of fenofibrate on dyslipidemia in hypertensive patients with metabolic syndrome and chronic kidney disease
Abstract
Short-term administration of fenofibrate appears to be an effective and relative safe in hypertensive patients with metabolic syndrome and stage 2-4 chronic kidney disease. It is necessary to monitir carefully all patients with chronic kidney disease on fibrate therapy for early detection of severe adverse drug effects.